Why Dundee Precious Metals (DPMLF) Could Beat Earnings Estimates Again
When looking at the last two reports, this company has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 12.75%, on average, in the last two quarters.
For the most recent quarter, Dundee Precious Metals was expected to post earnings of $0.32 per share, but it reported $0.27 per share instead, representing a surprise of 18.52%. For the previous quarter, the consensus estimate was $0.43 per share, while it actually produced $0.46 per share, a surprise of 6.98%.
With this earnings history in mind, recent estimates have been moving higher for Dundee Precious Metals. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the company is positive, which is a great sign of an earnings beat, especially when you combine this metric with its nice Zacks Rank.
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Dundee Precious Metals currently has an Earnings ESP of +9.74%, which suggests that analysts have recently become bullish on the company's earnings prospects. This positive Earnings ESP when combined with the stock's Zacks Rank #1 (Strong Buy) indicates that another beat is possibly around the corner. We expect the company's next earnings report to be released on July 31, 2025.
With the Earnings ESP metric, it's important to note that a negative value reduces its predictive power; however, a negative Earnings ESP does not indicate an earnings miss.
Many companies end up beating the consensus EPS estimate, but that may not be the sole basis for their stocks moving higher. On the other hand, some stocks may hold their ground even if they end up missing the consensus estimate.
Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Dundee Precious Metals Inc. (DPMLF) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 hours ago
- Yahoo
LifeStance Health Group (LFST) Reports Q2 Loss, Tops Revenue Estimates
LifeStance Health Group (LFST) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.06 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +66.67%. A quarter ago, it was expected that this outpatient mental health services provider would post a loss of $0.04 per share when it actually produced break-even earnings, delivering a surprise of +100%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. LifeStance Health, which belongs to the Zacks Medical - Outpatient and Home Healthcare industry, posted revenues of $345.31 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.02%. This compares to year-ago revenues of $312.33 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. LifeStance Health shares have lost about 47.1% since the beginning of the year versus the S&P 500's gain of 7.9%. What's Next for LifeStance Health? While LifeStance Health has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for LifeStance Health was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.01 on $359.78 million in revenues for the coming quarter and -$0.06 on $1.42 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Outpatient and Home Healthcare is currently in the top 27% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, RadNet (RDNT), has yet to report results for the quarter ended June 2025. The results are expected to be released on August 10. This operator of medical diagnostic imaging centers is expected to post quarterly earnings of $0.17 per share in its upcoming report, which represents a year-over-year change of +6.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. RadNet's revenues are expected to be $488.57 million, up 6.3% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report LifeStance Health Group, Inc. (LFST) : Free Stock Analysis Report RadNet, Inc. (RDNT) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
a day ago
- Yahoo
APA (APA) Reports Q2 Earnings: What Key Metrics Have to Say
APA (APA) reported $2.61 billion in revenue for the quarter ended June 2025, representing a year-over-year decline of 6.5%. EPS of $0.87 for the same period compares to $1.17 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $2.07 billion, representing a surprise of +26.08%. The company delivered an EPS surprise of +93.33%, with the consensus EPS estimate being $0.45. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Here is how APA performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Production volume per day - Total: 465.08 KBOE/D versus 457.24 KBOE/D estimated by eight analysts on average. Production volume per day - Natural gas - Total: 894.1 millions of cubic feet per day versus the seven-analyst average estimate of 902.9 millions of cubic feet per day. Production volume per day - Oil - Total: 235.24 thousands of barrels of oil per day compared to the 230.62 thousands of barrels of oil per day average estimate based on six analysts. Production volume per day - NGL - Total: 80.82 thousands of barrels of oil per day versus 76.12 thousands of barrels of oil per day estimated by six analysts on average. Revenues- United States: $1.38 billion versus the two-analyst average estimate of $957.89 million. The reported number represents a year-over-year change of +16.3%. Revenues- North Sea: $166 million versus the two-analyst average estimate of $168.18 million. The reported number represents a year-over-year change of -37.8%. Revenues- Egypt: $630 million versus the two-analyst average estimate of $616.41 million. The reported number represents a year-over-year change of -15.6%. Oil, natural gas, and natural gas liquids production revenues- Natural gas revenues: $184 million versus $182.92 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +36.3% change. Oil, natural gas, and natural gas liquids production revenues- Natural gas liquids revenues: $153 million compared to the $139.21 million average estimate based on four analysts. The reported number represents a change of -3.8% year over year. Oil, natural gas, and natural gas liquids production revenues: $1.72 billion versus the four-analyst average estimate of $1.62 billion. The reported number represents a year-over-year change of -21.9%. Oil, natural gas, and natural gas liquids production revenues- Oil revenues: $1.38 billion compared to the $1.32 billion average estimate based on four analysts. The reported number represents a change of -27.6% year over year. Purchased oil and gas sales: $460 million versus the three-analyst average estimate of $418.35 million. The reported number represents a year-over-year change of +34.5%. View all Key Company Metrics for APA here>>> Shares of APA have returned -4.6% over the past month versus the Zacks S&P 500 composite's +1.9% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report APA Corporation (APA) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
Femasys Inc. (FEMY) Reports Q2 Loss, Lags Revenue Estimates
Femasys Inc. (FEMY) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.21 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +11.11%. A quarter ago, it was expected that this company would post a loss of $0.17 per share when it actually produced a loss of $0.23, delivering a surprise of -35.29%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Femasys, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.41 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 48.88%. This compares to year-ago revenues of $0.22 million. The company has topped consensus revenue estimates just once over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Femasys shares have lost about 19.8% since the beginning of the year versus the S&P 500's gain of 7.8%. What's Next for Femasys? While Femasys has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Femasys was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.14 on $1.7 million in revenues for the coming quarter and -$0.56 on $6.85 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 43% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Grail (GRAL), has yet to report results for the quarter ended June 2025. The results are expected to be released on August 12. This company is expected to post quarterly loss of $3.14 per share in its upcoming report, which represents a year-over-year change of +40.8%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Grail's revenues are expected to be $35.74 million, up 11.8% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Femasys Inc. (FEMY) : Free Stock Analysis Report GRAIL, Inc. (GRAL) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
